212 related articles for article (PubMed ID: 18543899)
1. Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting.
Cescato R; Erchegyi J; Waser B; Piccand V; Maecke HR; Rivier JE; Reubi JC
J Med Chem; 2008 Jul; 51(13):4030-7. PubMed ID: 18543899
[TBL] [Abstract][Full Text] [Related]
2. Novel sst(4)-selective somatostatin (SRIF) agonists. 2. Analogues with beta-methyl-3-(2-naphthyl)alanine substitutions at position 8.
Erchegyi J; Penke B; Simon L; Michaelson S; Wenger S; Waser B; Cescato R; Schaer JC; Reubi JC; Rivier J
J Med Chem; 2003 Dec; 46(26):5587-96. PubMed ID: 14667213
[TBL] [Abstract][Full Text] [Related]
3. Novel sst(4)-selective somatostatin (SRIF) agonists. 3. Analogues amenable to radiolabeling.
Erchegyi J; Waser B; Schaer JC; Cescato R; Brazeau JF; Rivier J; Reubi JC
J Med Chem; 2003 Dec; 46(26):5597-605. PubMed ID: 14667214
[TBL] [Abstract][Full Text] [Related]
4. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors.
Ginj M; Zhang H; Waser B; Cescato R; Wild D; Wang X; Erchegyi J; Rivier J; Mäcke HR; Reubi JC
Proc Natl Acad Sci U S A; 2006 Oct; 103(44):16436-41. PubMed ID: 17056720
[TBL] [Abstract][Full Text] [Related]
5. Novel sst(4)-selective somatostatin (SRIF) agonists. 1. Lead identification using a betide scan.
Rivier J; Erchegyi J; Hoeger C; Miller C; Low W; Wenger S; Waser B; Schaer JC; Reubi JC
J Med Chem; 2003 Dec; 46(26):5579-86. PubMed ID: 14667212
[TBL] [Abstract][Full Text] [Related]
6. Agonist properties of putative small-molecule somatostatin sst2 receptor-selective antagonists.
Nunn C; Langenegger D; Hurth K; Schmidt K; Fehlmann D; Hoyer D
Eur J Pharmacol; 2003 Apr; 465(3):211-8. PubMed ID: 12681432
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of 177Lu-DOTA-sst2 antagonist versus 177Lu-DOTA-sst2 agonist binding in human cancers in vitro.
Cescato R; Waser B; Fani M; Reubi JC
J Nucl Med; 2011 Dec; 52(12):1886-90. PubMed ID: 22068898
[TBL] [Abstract][Full Text] [Related]
8. Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications.
Fani M; Braun F; Waser B; Beetschen K; Cescato R; Erchegyi J; Rivier JE; Weber WA; Maecke HR; Reubi JC
J Nucl Med; 2012 Sep; 53(9):1481-9. PubMed ID: 22851637
[TBL] [Abstract][Full Text] [Related]
9. First clinical evidence that imaging with somatostatin receptor antagonists is feasible.
Wild D; Fani M; Behe M; Brink I; Rivier JE; Reubi JC; Maecke HR; Weber WA
J Nucl Med; 2011 Sep; 52(9):1412-7. PubMed ID: 21852357
[TBL] [Abstract][Full Text] [Related]
10. Ring size in octreotide amide modulates differently agonist versus antagonist binding affinity and selectivity.
Grace CR; Erchegyi J; Samant M; Cescato R; Piccand V; Riek R; Reubi JC; Rivier JE
J Med Chem; 2008 May; 51(9):2676-81. PubMed ID: 18410083
[TBL] [Abstract][Full Text] [Related]
11. Potent somatostatin undecapeptide agonists selective for somatostatin receptor 1 (sst1).
Rivier JE; Hoeger C; Erchegyi J; Gulyas J; DeBoard R; Craig AG; Koerber SC; Wenger S; Waser B; Schaer JC; Reubi JC
J Med Chem; 2001 Jun; 44(13):2238-46. PubMed ID: 11405660
[TBL] [Abstract][Full Text] [Related]
12. Highly potent cyclic disulfide antagonists of somatostatin.
Hocart SJ; Jain R; Murphy WA; Taylor JE; Coy DH
J Med Chem; 1999 Jun; 42(11):1863-71. PubMed ID: 10354394
[TBL] [Abstract][Full Text] [Related]
13. Novel sst(4)-selective somatostatin (SRIF) agonists. 4. Three-dimensional consensus structure by NMR.
Grace CR; Koerber SC; Erchegyi J; Reubi JC; Rivier J; Riek R
J Med Chem; 2003 Dec; 46(26):5606-18. PubMed ID: 14667215
[TBL] [Abstract][Full Text] [Related]
14. Selective central activation of somatostatin receptor 2 increases food intake, grooming behavior and rectal temperature in rats.
Stengel A; Goebel M; Wang L; Rivier J; Kobelt P; Monnikes H; Tache Y
J Physiol Pharmacol; 2010 Aug; 61(4):399-407. PubMed ID: 20814067
[TBL] [Abstract][Full Text] [Related]
15. Three-dimensional consensus structure of sst2-selective somatostatin (SRIF) antagonists by NMR.
Grace CR; Erchegyi J; Reubi JC; Rivier JE; Riek R
Biopolymers; 2008 Dec; 89(12):1077-87. PubMed ID: 18655144
[TBL] [Abstract][Full Text] [Related]
16. Novel, potent, and radio-iodinatable somatostatin receptor 1 (sst1) selective analogues.
Erchegyi J; Cescato R; Grace CR; Waser B; Piccand V; Hoyer D; Riek R; Rivier JE; Reubi JC
J Med Chem; 2009 May; 52(9):2733-46. PubMed ID: 19351180
[TBL] [Abstract][Full Text] [Related]
17. A new
Mansi R; Abid K; Nicolas GP; Del Pozzo L; Grouzmann E; Fani M
EJNMMI Res; 2020 Aug; 10(1):90. PubMed ID: 32757150
[TBL] [Abstract][Full Text] [Related]
18. Design, preparation and biological evaluation of a
Behnammanesh H; Jokar S; Erfani M; Geramifar P; Sabzevari O; Amini M; Mazidi SM; Hajiramezanali M; Beiki D
Bioorg Chem; 2020 Jan; 94():103381. PubMed ID: 31662215
[TBL] [Abstract][Full Text] [Related]
19. Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues.
Waser B; Tamma ML; Cescato R; Maecke HR; Reubi JC
J Nucl Med; 2009 Jun; 50(6):936-41. PubMed ID: 19443580
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]